The Fibrolamellar Cancer Foundation (FCF) has partnered with the Cancer Research Institute to support research that aims to develop immunotherapeutic strategies for treating this ultra-rare form of liver cancer, which primarily affects teens and young adults. In 2016, the inaugural round of three postdoctoral fellowships and one investigator grant totaling $641,500 was awarded to scientists at four U.S. universities.

*Immunotherapy results may vary from patient to patient.